Tulisokibart Posts Efficacy in Phase 2b for Moderate-to-Severe HS
Tulisokibart demonstrated efficacy in a Phase 2b study of patients with moderate to severe hidradenitis suppurativa, HCPLive reports, marking the candidate as one to watch.
Topic
Phase 2b Trial
Topic
Phase 2b Trial
Tulisokibart Hits Primary Endpoint in Phase 2b HS Trial
Tulisokibart met its primary endpoint in a Phase 2b hidradenitis suppurativa trial, advancing a new anti-TNF candidate toward Pha…